The Oncology Institute, Inc. (TOI): Price and Financial Metrics
GET POWR RATINGS... FREE!
TOI POWR Grades
- Sentiment is the dimension where TOI ranks best; there it ranks ahead of 87.61% of US stocks.
- TOI's strongest trending metric is Growth; it's been moving down over the last 177 days.
- TOI's current lowest rank is in the Growth metric (where it is better than 5.4% of US stocks).
TOI Stock Summary
- With a one year PEG ratio of 0.54, ONCOLOGY INSTITUTE INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.96% of US stocks.
- With a year-over-year growth in debt of 2,066.58%, ONCOLOGY INSTITUTE INC's debt growth rate surpasses 98.91% of about US stocks.
- ONCOLOGY INSTITUTE INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -447.76%, greater than the shareholder yield of merely 1.27% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to ONCOLOGY INSTITUTE INC, a group of peers worth examining would be SWIM, TRC, CBZ, MP, and TIRX.
- To dig deeper into the stock's financial statements, go to TOI's page on browse-edgar?action=getcompany&CIK=0001799191.
TOI Valuation Summary
- TOI's price/earnings ratio is 106; this is 352.99% higher than that of the median Healthcare stock.
- Over the past 33 months, TOI's price/sales ratio has gone down 1.4.
Below are key valuation metrics over time for TOI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TOI | 2022-12-02 | 0.5 | 0.8 | 106.0 | 428.7 |
| TOI | 2022-12-01 | 0.4 | 0.8 | 101.7 | 416.5 |
| TOI | 2022-11-30 | 0.4 | 0.8 | 101.7 | 416.5 |
| TOI | 2022-11-29 | 0.4 | 0.8 | 104.6 | 424.7 |
| TOI | 2022-11-28 | 0.4 | 0.8 | 101.7 | 416.5 |
| TOI | 2022-11-25 | 0.5 | 0.9 | 109.7 | 439.2 |
TOI Stock Price Chart Interactive Chart >
TOI Price/Volume Stats
| Current price | $1.33 | 52-week high | $12.66 |
| Prev. close | $1.47 | 52-week low | $1.31 |
| Day low | $1.31 | Volume | 344,300 |
| Day high | $1.45 | Avg. volume | 130,606 |
| 50-day MA | $3.57 | Dividend yield | N/A |
| 200-day MA | $5.80 | Market Cap | 96.21M |
The Oncology Institute, Inc. (TOI) Company Bio
The Oncology Institute, Inc., an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, outpatient stem cell transplants and transfusions programs, and 24/7 patient support. The company was founded in 2007 and is headquartered in Cerritos, California.
Latest TOI News From Around the Web
Below are the latest news stories about ONCOLOGY INSTITUTE INC that investors may wish to consider to help them evaluate TOI as an investment opportunity.
The Oncology Institute Expands into Miami-Dade County, Hires National Oncology Leader Dr. Roberto OchoaTOI continues expansion in South FloridaCERRITOS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, announced its entrance into Miami-Dade County, Florida with the acquisition of Hematology/Oncology Associates of Miami and the addition of a Senior Medical Director for Florida, further strengthening their investment in South Florida. Dr. Roberto Ochoa, former National Director, Hemat |
Analysts Offer Insights on Healthcare Companies: Sol-Gel Technologies (SLGL), Zentalis Pharmaceuticals (ZNTL) and Oncology Institute, Inc. (TOI)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sol-Gel Technologies (SLGL – Research Report), Zentalis Pharmaceuticals (ZNTL – Research Report) and Oncology Institute, Inc. (TOI – Research Report) with bullish sentiments. Sol-Gel Technologies (SLGL) Raymond James analyst Elliot Wilbur maintained a Buy rating on Sol-Gel Technologies today and set a price target of $13.00. The company's shares closed last Friday at $4.74, close to its 52-week low of $3.94. According to TipRanks. |
The Oncology Institute Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 GuidanceCERRITOS, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based community oncology groups in the United States, today reported financial results for its third quarter ended September 30, 2022. Recent Operational Highlights Completed a $110 million strategic investment from Deerfield Management Company, L.P. through secured senior convertible notes on August 9, 2022Increased market count to 14 during the third quarter, including three |
The Oncology Institute to Participate at the Credit Suisse 31st Annual Healthcare ConferenceCERRITOS, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that its Chief Executive Officer, Brad Hively, and its Chief Financial Officer, Mihir Shah, will participate in the Credit Suisse 31st Annual Healthcare Conference in Rancho Palos Verdes on Thursday, November 10. About The Oncology Institute, Inc. Founded in 2007, TOI is advancing oncology by delivering highly special |
The Oncology Institute Announces Third Quarter 2022 Earnings Release Date and Conference CallCERRITOS, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute, LLC (“TOI”) (NASDAQ: TOI) one of the largest value-based oncology groups in the United States, today announced that the company will release its third quarter results after the market close on Wednesday November 9, 2022, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-856 |
TOI Price Returns
| 1-mo | -61.00% |
| 3-mo | -78.02% |
| 6-mo | -77.76% |
| 1-year | -80.50% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -86.36% |
| 2021 | -9.72% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...